Wells Fargo & Company Uro Gen Pharma Ltd. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 215,739 shares of URGN stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,739
Previous 215,841
0.05%
Holding current value
$2.3 Million
Previous $3.62 Million
24.36%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$40.3 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$39.7 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.5 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$23.2 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $242M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...